Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions

Pharmacology Research and Perspectives

Volumn 3, Issue 1, 2015, Pages 1-10

  Gao, Yonglin ^a   Peterson, Sean ^a   Masri, Bernard ^a   Hougland, M Tyler ^b   Adham, Nika ^c   Gyertyán, Istvan ^d   Kiss, Béla ^d   Caron, Marc G ^a   El Mallakh, Rif S ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d GEDEON RICHTER LTD   (Hungary)

Author keywords

Animal models; Antipsychotics; Arrestin; Dopamine receptors; Protein kinases

Indexed keywords

ARIPIPRAZOLE; BETA ARRESTIN; CARIPRAZINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LITHIUM; OUABAIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EC50; EXPERIMENTAL HYPERACTIVITY; HUMAN; HUMAN CELL; MALE; MANIA; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 84983232809     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.73     Document Type: Article

References (47)

1. Alimohamad H, Rajakumar N, Seah YH, Rushlow W (2005). Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 57: 533-542.
2. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, et al. (2011). Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA 108: 18488-18493.
3. Beaulieu JM, Gainetdinov RR (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63: 182-217.
4. Beaulieu JM, Gainetdinov RR, Caron MG (2007a). The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28: 166-172.
5. Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, Gainetdinov RR, et al. (2007b). Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 27: 881-885.
6. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, et al. (2008). A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132: 125-136.
7. Beaulieu JM, Gainetdinov RR, Caron MG (2009). Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49: 327-347.
8. Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, et al. (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl:41-49.
9. Boireau A, Meunier M, Imperato A (1998). Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole. J Pharm Pharmacol 50: 1293-1297.
10. Changaris DG, Porter JL, Miller JJ, Levy RS (1988). Des-Leu angiotensin I: biosynthesis and drinking response. Regul Pept 20: 273-280.
11. Citrome L (2013a). Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther 30: 102-113.
12. Citrome L (2013b). Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther 30: 114-126.
13. Cousins DA, Butts K, Young AH (2009). The role of dopamine in bipolar disorder. Bipolar Disord 11: 787-806.
14. El-Mallakh RS, Harrison LT, Li R, Changaris DG, Levy RS (1995). An animal model for mania: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 19: 955-962.
15. El-Mallakh RS, El-Masri MA, Huff MO, Li XP, Decker S, Levy RS (2003). Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disord 5: 362-365.
16. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131-137.
17. Freyberg Z, Ferrando SJ, Javitch JA (2010). Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 167: 388-396.
18. Gao Y, Payne RS, Schurr A, Hougland T, Lord J, Herman L, et al. (2011). Memantine reduces mania-like symptoms in animal models. Psychiatry Res 188: 366-371.
19. Ginovart N, Kapur S (2012) Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol: 26-52.
20. Grunder G (2010). Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs 11: 823-832.
21. Herman L, Hougland T, El-Mallakh RS (2007). Mimicking human bipolar ion dysregulation models mania in rats. Neurosci Biobehav Rev 31: 874-881.
22. Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, et al. (2000). D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2 + currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci 20: 8987-8995.
23. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69: 776-786.
24. Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, et al. (2004). Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry 56: 698-700.
25. Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, et al. (2010). Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 31: 381-390.
26. Khundmiri SJ, Metzler MA, Ameen M, Amin V, Rane MJ, Delamere NA (2006). Ouabain induces cell proliferation through calcium-dependent phosphorylation of Akt (protein kinase B) in opossum kidney proximal tubule cells. Am J Physiol Cell Physiol 291: C1247-C1257.
27. Khundmiri SJ, Amin V, Henson J, Lewis J, Ameen M, Rane MJ, et al. (2007). Ouabain stimulates protein kinase B (Akt) phosphorylation in opossum kidney proximal tubule cells through an ERK-dependent pathway. Am J Physiol Cell Physiol 293: C1171-C1180.
28. Kirshenbaum GS, Clapcote SJ, Duffy S, Burgess CR, Petersen J, Jarowek KJ, et al. (2011). Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+, K + -ATPase á3 sodium pump. Proc Natl Acad Sci USA 108: 18144-18149.
29. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333: 328-340.
30. Koros E, Dorner-Ciossek C (2007). The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect 20: 437-445.
31. Lai WS, Xu B, Westphal KG, Paterlini M, Olivier B, Pavlidis P, et al. (2006). Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci USA 103: 16906-16911.
32. Li X, Jope RS (2010). Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 35: 2143-2154.
33. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS (2004). In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29: 1426-1431.
34. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS, et al. (2007). Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 61: 216-222.
35. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, et al. (2008). Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105: 13656-13661.
36. Mukherjee BP, Bailey PT, Pradhan SN (1976). Temporal and regional differences in brain concentrations of lithium in rats. Psychopharmacology 48: 119-121.
37. Nicodemus KK, Law AJ, Radulescu E, Luna A, Kolachana B, Vakkalanka R, et al. (2010). Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry 67: 991-1001.
38. O'Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, Berry GT, et al. (2011). Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest 121: 3756-3762.
39. Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I, et al. (2006). Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 26: 9022-9029.
40. Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, Lerer B, et al. (2005). Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry 58: 446-450.
41. Silva E, Soares-da-Silva P (2012). New Insights into the Regulation of Na(+), K(+)-ATPase by Ouabain. Int Rev Cell Mol Biol 294: 99-132.
42. Simpson EH, Kellendonk C, Kandel E (2010). A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65: 585-596.
43. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R, et al. (2008). Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 118: 2200-2208.
44. Webb CK, McCudden CR, Willard FS, Kimple RJ, Siderovski DP, Oxford GS (2005). D2 dopamine receptor activation of potassium channels is selectively decoupled by Galpha-specific GoLoco motif peptides. J Neurochem 92: 1408-1418.
45. Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011). Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36: 375-389.
46. Young JW, Henry BL, Geyer MA (2011). Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol 164: 1263-1284.
47. Yu HS, Kim SH, Park HG, Kim YS, Ahn YM (2010). Activation of Akt signaling in rat brain by intracerebroventricular injection of ouabain: a rat model for mania. Prog Neuropsychopharmacol Biol Psychiatry 34: 888-894.